Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Su K. Metcalfe, MD, MPH, Michael T

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer Hilâl Tekatli, MD, Niels Haasbeek,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B Martin.

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Mitotic Inhibitors Journal of Thoracic Oncology

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Visceral Pleural Invasion Classification in Non-small Cell Lung Cancer

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Relevance of Our Multimodality Prognostic Score

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non– Small-Cell Lung Cancer Seung Jun Lee, MD, Jinwoo Lee, MD, Young.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Induction Therapy For Locally Advanced Thymoma

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Mark A. Socinski, MD Journal of Thoracic Oncology

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Lucyna Kepka, MD, Dobromira Tyc-Szczepaniak, MD, Krzysztof Bujko, MD Journal of Thoracic Oncology Volume 4, Issue 7, Pages 853-861 (July 2009) DOI: 10.1097/JTO.0b013e3181a97dda Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Overall survival. Journal of Thoracic Oncology 2009 4, 853-861DOI: (10.1097/JTO.0b013e3181a97dda) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Relationship of weight loss of more than 5% to overall survival, p = 0.02. Journal of Thoracic Oncology 2009 4, 853-861DOI: (10.1097/JTO.0b013e3181a97dda) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Relationship of gross tumor volume to overall survival, p = 0.003. GTV, gross tumor volume. Journal of Thoracic Oncology 2009 4, 853-861DOI: (10.1097/JTO.0b013e3181a97dda) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Relationship of the presence of bulky mediastinal disease to overall survival, p = 0.03. Journal of Thoracic Oncology 2009 4, 853-861DOI: (10.1097/JTO.0b013e3181a97dda) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Relationship of chemotherapy to overall survival, p = 0.25. Journal of Thoracic Oncology 2009 4, 853-861DOI: (10.1097/JTO.0b013e3181a97dda) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Relationship of total dose to overall survival, p = 0.76. Journal of Thoracic Oncology 2009 4, 853-861DOI: (10.1097/JTO.0b013e3181a97dda) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions